Industry News

• Tradipitant effective in preventing motion sickness  Vanda Pharma announced that tradipitant, a neurokinin-1 receptor antagonist, was effective in treating motion sickness in a clinical study conducted in the Pacific Ocean. Vanda intends to initiate a Phase III program in Motion Sickness, with a plan to file for marketing authorization in 2020.
  July 16, 2019  
• Seattle Genetics reports second quarter 2019 financial results  Seattle Genetics reported the net loss for the 2019 second quarter was $79.2 million versus net income of $76.3 million for the same 2018 period. Total revenues in the 2019 second quarter increased to $218.4 million versus $170.2 million in the same 2018 period.
  July 16, 2019  
• Aratana Therapeutics' stockholders adopt merger agreement with Elanco Animal Health  Aratana Therapeutics reported 72% (35,269,237) of the Company's common stock outstanding as of the July 14, 2019 record date adopted the merger agreement. Aratana stockholders will receive 0.1481 share of Elanco common stock and one contingent value right for each share of Aratana common stock.
  July 16, 2019  
• Eyenovia announces underwriters’ full exercise of over-allotment option  Eyenovia announced that underwriters of its public offering of common stock have fully exercised their option to purchase an additional 658,273 shares at the public offering price of $2.78 per share. Net proceeds increased to approximately $13.0 million.
  July 16, 2019  
• Arrowhead Pharmaceuticals receives Orphan Drug designation for ARO-ANG3  Arrowhead Pharmaceuticals announced the FDA has granted orphan drug designation to ARO-ANG3 for the treatment of homozygous familial hypercholesterolemia (HoFH). The company began dosing ARO-ANG3 in a first-in-human study (AROANG1001) in January 2019.
  July 16, 2019  
• Persistent HIV in central nervous system linked to cognitive impairment  Many people with HIV on ART have viral genetic material in the cells of their CSF, and these individuals are more likely to experience memory and concentration problems, according to new data publishedin the Jour nal of Clinical Investigation.
  July 16, 2019  
• LivaNova combats leg ischemia with breakthrough bidirectional cannula  LivaNova announced it has launched its innovative arterial femoral cannula, Bi-Flow, designed to prevent limb ischemia during cardiac surgery. LivaNova Bi-Flow received CE Mark earlier this year and is the only bidirectional arterial cannula designed to prevent leg ischemia during cardiac surgery.
  July 16, 2019  
• llumina expands genomics accelerator to Cambridge, UK  Illumina announced the global expansion of Illumina Accelerator to Cambridge, United Kingdom. Founded in the San Francisco Bay Area in 2014, Illumina Accelerator is a company creation engine focused on partnering with entrepreneurs to build breakthrough genomics startups.
  July 16, 2019  
• Kite announces plans to bolster industry-leading cell therapy manufacturing capabilities  Kite, a Gilead Company, announced plans for a new 67,000-square-foot facility in Oceanside, California, dedicated to the development and manufacturing of viral vectors, a critical starting material in the production of cell therapies.
  July 16, 2019  
• Seattle Genetics and Astellas announce submission of BLA to FDA for enfortumab vedotin  Seattle Genetics and Astellas Pharma announced submission of a Biologics License Application for accelerated approval to the FDA for the investigational agent enfortumab vedotin for treatment of patients with locally advanced or metastatic urothelial cancer.
  July 16, 2019  

   (next 10 articles)